In a patient receiving chronic glucocorticoid therapy, what additional medications should be prescribed besides calcium and vitamin D?

Bisphosphonates Are the Primary Additional Medication Beyond Calcium and Vitamin D

For patients on chronic glucocorticoids (≥3 months at ≥2.5 mg/day prednisone equivalent), oral bisphosphonates (alendronate or risedronate) should be added to calcium and vitamin D supplementation in those at moderate-to-high fracture risk. 1

Risk-Stratified Treatment Algorithm

Step 1: Assess Fracture Risk

Perform initial fracture risk assessment within 6 months of starting glucocorticoids using:

• For adults ≥40 years: FRAX with glucocorticoid dose adjustment (multiply major osteoporotic fracture risk by 1.15 and hip fracture risk by 1.2 if dose >7.5 mg/day), bone mineral density (BMD), and vertebral fracture assessment 2
• For adults <40 years: History of fractures, BMD z-scores, and glucocorticoid dose/duration 1

Step 2: Universal Baseline Supplementation

All patients on chronic glucocorticoids require:

• Calcium: 1,000-1,200 mg/day (elemental) 1
• Vitamin D: 600-800 IU/day (target serum level ≥20 ng/ml) 1
• Lifestyle modifications: Weight-bearing exercise, smoking cessation, limit alcohol to 1-2 drinks/day, maintain healthy weight 1

Step 3: Add Pharmacologic Osteoporosis Treatment Based on Risk

Adults ≥40 Years at Moderate-to-High Risk:

First-line: Oral bisphosphonates (alendronate or risedronate) 1

• Preferred due to proven fracture reduction, safety profile, and cost-effectiveness
• Strong recommendation for high-risk patients; conditional for moderate-risk patients

Second-line alternatives if oral bisphosphonates inappropriate:

1. IV bisphosphonates (zoledronic acid, ibandronate) - if absorption concerns or adherence issues 1
2. Teriparatide or abaloparatide (PTH/PTHrP agonists) - conditionally recommended, especially for very high fracture risk 2
3. Denosumab - use with caution; avoid in transplant patients on multiple immunosuppressants 1
4. Raloxifene (postmenopausal women only) - limited data, concerns about venous thromboembolism 1

Adults <40 Years at Moderate-to-High Risk:

Oral bisphosphonates remain first choice, though evidence is more limited 1

• Use caution in women of childbearing potential; ensure adequate contraception 1

Children 4-17 Years with Osteoporotic Fracture:

Oral bisphosphonate (or IV if oral contraindicated) if continuing glucocorticoids ≥0.1 mg/kg/day for ≥3 months 1

• Plus calcium 1,000 mg/day and vitamin D 600 IU/day 1

Critical Nuances and Pitfalls

Very High-Risk Patients

For those with prior osteoporotic fractures, BMD t-score ≤-3.5, or very high glucocorticoid doses (≥30 mg/day for >30 days or cumulative ≥5 g/year), consider anabolic agents (teriparatide/abaloparatide) over bisphosphonates as they may provide superior fracture protection 2

Treatment Failure

If fracture occurs after ≥18 months of oral bisphosphonate therapy OR significant BMD loss (≥10%/year), switch to different drug class (teriparatide, denosumab, or IV bisphosphonate if absorption suspected) 1

Duration of Therapy

• Continue osteoporosis medication as long as glucocorticoids are continued 3
• After 5 years of oral bisphosphonates: reassess fracture risk; if moderate-to-high risk persists, continue treatment or switch to alternative agent 1
• If glucocorticoids discontinued and fracture risk becomes low, stop osteoporosis medication but continue calcium and vitamin D 1

Special Populations

• Transplant recipients: Avoid denosumab due to infection risk with multiple immunosuppressants; consult metabolic bone disease specialist for renal transplant patients 1
• Pregnant/childbearing potential: Only calcium, vitamin D, and lifestyle modifications; bisphosphonates contraindicated 1

Monitoring

Repeat BMD with vertebral fracture assessment every 1-2 years during treatment 2, 4

Common Clinical Error

The most significant pitfall is prescribing only calcium and vitamin D without risk-stratifying patients. This combination alone does not prevent bone loss in patients receiving medium-to-high dose glucocorticoids 3. The 2017 ACR guidelines represent a paradigm shift toward more aggressive early intervention with bisphosphonates for at-risk patients, supported by fracture reduction data in this population 1, 5.